| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Low Visibility Led To Enpath Acquisition
Posted on 05/02/2007 06:29:54 | Link | Post Comment
by Sara Calabro
Med Tech Sentinel
Enpath (NPTH) was forced to give up its independence because it wasn’t getting enough attention from analysts. That’s what CFO Scott Youngstrom told the Pioneer Press following yesterday’s announcement that Enpath would be acquired by Greatbatch (GB) for $102 million.
“With a market capitalization of about $70 million before the deal was announced, Enpath Medical wasn’t large enough to get the attention of many stock analysts who follow medical-technology companies,” Youngstrom told the paper. “That lack of visibility limited Enpath’s independence.”
And Thomas Letscher, a Minneapolis attorney with Oppenheimer Wolff Donnelly, told the Press that Enpath is not alone in its struggle to stay afloat on its own. He said other public med tech companies with market caps under $200 million have wrestled with the same problem over the last 10 years. “Part of the problem,” he told the paper, ”is that consolidation among investment banks has meant the surviving analysts often must focus their limited time on larger medical-technology companies.” He explained, “In the mid-1990s, there were companies going public in the pre-revenue stage. That’s not really the case any more, or it’s certainly significantly more difficult for that to happen.”
Source: OneMedPlace.com
_____________________
Med Tech Sentinel
Enpath (NPTH) was forced to give up its independence because it wasn’t getting enough attention from analysts. That’s what CFO Scott Youngstrom told the Pioneer Press following yesterday’s announcement that Enpath would be acquired by Greatbatch (GB) for $102 million.“With a market capitalization of about $70 million before the deal was announced, Enpath Medical wasn’t large enough to get the attention of many stock analysts who follow medical-technology companies,” Youngstrom told the paper. “That lack of visibility limited Enpath’s independence.”
And Thomas Letscher, a Minneapolis attorney with Oppenheimer Wolff Donnelly, told the Press that Enpath is not alone in its struggle to stay afloat on its own. He said other public med tech companies with market caps under $200 million have wrestled with the same problem over the last 10 years. “Part of the problem,” he told the paper, ”is that consolidation among investment banks has meant the surviving analysts often must focus their limited time on larger medical-technology companies.” He explained, “In the mid-1990s, there were companies going public in the pre-revenue stage. That’s not really the case any more, or it’s certainly significantly more difficult for that to happen.”
Source: OneMedPlace.com
_____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home